Anna Lövqvist
Uppsala University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anna Lövqvist.
International Journal of Radiation Oncology Biology Physics | 1994
Lars Gedda; Christina Grönvik; Torbjörn Hartman; Annelie Lindström; Peter Lindström; Hans Lundqvist; Anna Lövqvist; Jonas Malmqvist; Pär Olsson; Magnus Essand; Jan Pontén; Stefan Sjöberg; Bengt Westermark
PURPOSE Gliomas, squamous carcinomas and different adenocarcinomas from breast, colon and prostate might have an increased number of epidermal growth factor (EGF) receptors. The receptors are, in these cases, candidates for binding of receptor specific toxic conjugates that might inactivate cellular proliferation. The purpose of this study was to evaluate whether it is reasonable to try ligand-dextran based conjugates for therapy. METHODS AND MATERIALS EGF or TGF alpha were conjugated to dextran and binding, internalization, retention and degradation of eight types of such conjugates were analyzed in EGF-receptor amplified glioma cells. The conjugates were labelled with radioactive nuclides to allow detection and two of the conjugates were carrying boron in the form of carboranyl amino acids or aminoalkyl-carboranes. Comparative binding tests, applying 125I-EGF, were made with cultured breast, colon and prostate adenocarcinoma, glioma and squamous carcinoma cells. Some introductory tests to label with 76Br for positron emission tomography and with 131I for radionuclide therapy were also made. RESULTS The dextran part of the conjugates did not prevent receptor specific binding. The amount of receptor specific binding varied between the different types of conjugates and between the tested cell types. The dextran part improved intracellular retention and radioactive nuclides were retained for at least 20-24 h. The therapeutical effect improved when 131I was attached to EGF-dextran instead of native EGF. CONCLUSION The improved cellular retention of the ligand-dextran conjugates is an important property since it gives extended exposure time when radionuclides are applied and flexibility in the choice of time for application of neutrons in boron neutron capture therapy (BNCT). It is possible that ligand-dextran mediated BNCT might allow, if the applied neutron fields covers rather wide areas around the primary tumor, locally spread cells that otherwise would escape treatment to be inactivated.
Journal of Internal Medicine | 1993
Anna Lövqvist; H. Emanuelsson; J. Nilsson; Hans Lundqvist
Abstract. Restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) remains an unsolved medical problem. The search for the underlying pathophysiological mechanisms have identified intimal proliferation of smooth muscle cells (SMC) to be the prevailing cause of late restenosis, with endothelial cells (EC) and platelets being important participators in the process. According to the most accepted present theory, SMC would be stimulated to migrate and proliferate shortly after the angioplasty by the release of growth factors from injured EC and accumulated platelets. However, clinical trials of agents interfering with these mechanisms have not significantly diminished the rate of restenosis, which suggest both that our knowledge of the process is incomplete, and that new ways of administrating the agents may be required.
Acta Oncologica | 1999
Mark Lubberink; Hans Lundqvist; Jan-Erik Westlin; Vladimir Tolmachev; Harald Schneider; Anna Lövqvist; Anders Sundin
Positron emission tomography (PET) is a medical imaging tool with high resolution and good quantitative properties, which makes it suitable for in vivo quantification of radioimmunotargeting agents. Most radionuclides used in radioimmunotherapy have positron-emitting analogues, which can be used for PET imaging, and this opens the possibility of performing dosimetry with PET. These isotopes, however, often emit gamma radiation and high-energy positrons in their decay, influencing the imaging properties of PET. Spatial resolution, reconstructed background and line source recovery for a number of non-pure positron emitters were investigated and compared with the imaging properties of 18F. PET imaging properties did not degrade severely for these non-pure positron emitters, but caution has to be applied when doing quantitative measurements. To assess the possibility of conducting PET studies during therapy, by combining, for example, a small amount of 124I with 131I, the influence of the presence of large amounts of gamma radiation on PET count rate characteristics was studied. The results of these studies were related to the necessary amounts of radioactivity needed for treatment of post-operative remains of glioma. The results indicate that the count rate capabilities of 2D PET permit PET studies for dose evaluation during radioimmunotherapy.
Nuclear Medicine and Biology | 1995
Anna Lövqvist; Anders Sundin; Håkan Ahlström; Hans Lundqvist
For the application of anti-tumor monoclonal antibodies (MAbs) in positron emission tomography (PET), labeling radionuclides with half-lives allowing a suitable time frame for imaging are required. The anti-CEA MAb 38S1 was labeled with the positron emitting nuclide 76Br (t1/2 16 h) using bromoperoxidase (BPO), and subsequently affinity purified. A procedure was devised to allow reproducible production of MAb-preparations of high immunoreactivity and with acceptable bromination yield. The biological activity of 76Br-38S1 was retained and comparable to that of chloramine-T labeled 125I-38S1, as tested in vitro.
Archive | 1996
Lars Gedda; Christina Grönvik; Torbjörn Hartman; Annelie Lindström; Hans Lundqvist; Anna Lövqvist; Jonas Malmqvist; Pär Olsson; Jan Pontén; Stefan Sjöberg; Anna Sjöström; Bo Stenerlöw; Nina Tilly; Magnus Essand; Werner Tjarks; Bengt Westermark
The binary nature of boron neutron capture therapy, BNCT, is an advantage because the tumor-seeking substance can be activated at any chosen time and because the neutron field can be delivered to selected areas so that exposure of critical healthy organs, which might contain significant amounts of boron, can be avoided. The tumor selective action should work in spite of the fact that tumor cells often have an infiltrative growth pattern being mixed with populations of normal cells. The targeting principle should be based on well-characterized properties of the tumor cells such as appearence of tumor-associated antigens or overexpression of receptors. The targeting agent could be antibodies, antibody-fragments or receptor ligands. Presently, mainly monoclonal antibodies are considered as targeting substances but it has been claimed that current approaches are limited by low uptake in the tumors studied. Thus, it seems necessary to also consider other principles such as growth factor mediated targeting (1–4).
Applied Radiation and Isotopes | 1998
Vladimir Tolmachev; Anna Lövqvist; Lars Einarsson; Joachim Schultz; Hans Lundqvist
The Journal of Nuclear Medicine | 1997
Anna Lövqvist; Anders Sundin; Håkan Ahlström; Hans Lundqvist
Acta Oncologica | 1999
Hans Lundqvist; Mark Lubberink; Vladimir Tolmachev; Anna Lövqvist; Anders Sundin; Soheir Beshara; Alexander Bruskin; Jan-Erik Westlin
Medical Physics | 1999
Anna Lövqvist; Hans Lundqvist; Mark Lubberink; Vladimir Tolmachev; Anders Sundin
Acta Chemica Scandinavica | 1999
Ulrika Yngve; Elisabeth Hedberg; Anna Lövqvist; Vladimir Tolmachev; Bengt Långström